14.23 USD
↗ 0.87 (6.51%)AT CLOSE (11:59 AM EDT)
Summit Therapeutics Inc. Common Stock
SMMTNASDAQ • USD
14.27
↗ 0.04 (0.25%)
POST MARKET (AS OF 07:55 PM EDT)
Post Market
AS OF 07:55 PM EDT
14.27
↗ 0.04 (0.25%)
Market: CLOSED
Shares of Summit Therapeutics Inc. Common Stock (SMMT) are trading at $14.21. Technicals currently rate "Buy" while our fundamental analysis reads "Neutral". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On the valuation front, SMMT trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Aug 26, 2026.
Open?$14.75
High?$15.10
Low?$14.11
Prev. Close?$13.36
Volume?11.6M
Avg. Volume?5.0M
VWAP?$14.56
Rel. Volume?2.34x
Bid / Ask
Bid?$14.22 × 200
Ask?$14.28 × 1.0K
Spread?$0.06
Midpoint?$14.25
Valuation & Ratios
Market Cap?11.4B
Shares Out?797.7M
Float?137.5M
Float %?17.3%
P/E Ratio?N/A
P/B Ratio?18.02
EPS?-$1.07
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Address
601 BRICKELL KEY DRIVE
MIAMI, FL 33131
Phone: 305-203-2034
MIAMI, FL 33131
Phone: 305-203-2034
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?77
Short Sent.?16
Piotroski F-Score?0/9Weak
Altman Z-Score?47.86Safe
Confidence?55%Low
Short InterestSqueeze Risk
Short % of Float?27.22%Squeeze Risk
Short Interest?37.4M
Days to Cover?8.7
Free Float137.5M
Avg Daily Volume4.3M
Settlement Date2026-08-14
Financial Health
Current Ratio?6.96Strong
Quick Ratio?6.96Strong
Cash Ratio?4.05Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?18.02HIGH▾
Peers50
S&P9
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-12.5CHEAP▾
Peers100
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-135.9%WEAK▾
Peers50
S&P3
ROA?-113.8%WEAK▾
Peers50
S&P3
Cash Flow & Enterprise
FCF?$-459822000
Enterprise Value?$10.9B
Fundamentals ratios updated end of day